Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of resistance in HCV treatment.

Best practice & research. Clinical gastroenterology - 1 Aug 2012

Vermehren Johannes, Sarrazin Christoph

Abstract excerpt

The recent development of small molecule compounds that directly inhibit the viral life cycle represents a major milestone for the treatment of chronic hepatitis C virus (HCV) infection. These new drugs that are collectively termed direct-acting antivirals (DAA) include a range of inhibitors of the non-structural (NS) 3/4A protease, NS5B polymerase and NS5A protein. Two NS3/4A protease inhibitors (boceprevir and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Interferon-alpha
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 23199507
DOI: 10.1016/j.bpg.2012.09.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of resistance in HCV treatment.PMID 23199507Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.Semantic proximity Read ↗

The emerging field of HCV drug resistanceSemantic proximity Read ↗

Resistance mutations against HCV protease inhibitors and antiviral drug design.Semantic proximity Read ↗

Virologic Tools for HCV Drug Resistance TestingSemantic proximity Read ↗

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.Semantic proximity Read ↗

Update on hepatitis C virus resistance to direct-acting antiviral agents.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.Semantic proximity Read ↗

[RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].Semantic proximity Read ↗

Hepatitis C virus resistance to the new direct-acting antiviralsSemantic proximity Read ↗

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.